vasoactive-intestinal-peptide and pirarubicin

vasoactive-intestinal-peptide has been researched along with pirarubicin* in 1 studies

Other Studies

1 other study(ies) available for vasoactive-intestinal-peptide and pirarubicin

ArticleYear
Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Jul-01, Volume: 162

    In this study the chemotherapeutic agent Pirarubicin (PRB) which is known for its serious side effects was actively targeted to the breast cancer cells by uploading it to the biocompatible and biodegradable Sterically Stabilized Micelles (SSMs) made of 1,2- Distearoyl- sn- glycero‑3- phosphoethanolamine- N- methoxy‑ polyethylene glycol 2000 (DSPE-PEG

    Topics: Animals; Breast Neoplasms; Doxorubicin; Female; Humans; Mice; Mice, Nude; Micelles; Polyethylene Glycols; Vasoactive Intestinal Peptide

2021